Accelerate Diagnostics, Inc Form 8-K December 02, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported) December 2, 2015

Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

001-31822 (Commission File Number)

84-1072256 (IRS Employer Identification No.)

3950 South Country Club, Suite 470, Tucson, Arizona85714(Address of principal executive offices)(Zip Code)

(520) 365-3100 (Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

"Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

"Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

" Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

"Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On December 2, 2015, Accelerate Diagnostics, Inc. (the "Company") issued a press release announcing results from a pilot study to evaluate performance of its ID/AST System and Blood Culture Assay Kit and the Company's initiation of a larger trial to support U.S. Food and Drug Administration clearance. A copy of the Company's press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits. The following material is filed as an exhibit to this Current Report on Form 8-K:

Exhibit Number Description

99.1 Press Release, dated December 2, 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ACCELERATE DIAGNOSTICS, INC. (Registrant)

Date: December 2, 2015

/s/ Steve Reichling Steve Reichling Chief Financial Officer

EXHIBIT INDEX

Exhibit Number Description

99.1 Press Release, dated December 2, 2015